University of San Agustin gets Philippine patent for new antibiotic

Researchers at the University of San Agustin in Iloilo City have secured a Philippine patent for a new antibiotic, marking a significant breakthrough in the fight against drug-resistant infections. The Intellectual Property Office of the Philippines granted the patent, recognising the novelty and potential of the compound developed by the university's team.

The discovery comes at a time when the World Health Organization has repeatedly warned that antimicrobial resistance is one of the top global public health threats. The new antibiotic is designed to target bacteria that have become resistant to existing treatments, a problem that claims hundreds of thousands of lives each year.

How the discovery happened

The research team, led by faculty from the university's College of Pharmacy and Chemistry, isolated the compound from a soil microorganism. The process involved screening hundreds of microbial samples collected from various locations in Western Visayas.

Laboratory tests showed the compound was effective against several strains of drug-resistant bacteria, including methicillin-resistant Staphylococcus aureus and certain Gram-negative pathogens. The patent covers the compound itself as well as methods for its production and use.

Patent protection opens doors

The Philippine patent gives the university exclusive rights to the invention for 20 years from the filing date. This intellectual property protection is crucial for attracting investment and partnerships needed to develop the antibiotic into a marketable drug.

University officials said the patent validates years of painstaking research and positions the institution as a serious player in global pharmaceutical innovation. They are now exploring collaboration with pharmaceutical companies and research institutions to advance the drug through clinical trials.

From lab to bedside: the road ahead

Securing a patent is only the first step. The compound must now undergo extensive preclinical testing to assess its safety and efficacy in animal models. If those results are promising, the drug will enter human clinical trials, a process that can take a decade or more.

The University of San Agustin has a limited budget compared to big pharma, but officials are optimistic. They are applying for grants from the Department of Science and Technology and considering partnerships with international organisations that specialise in antibiotic development.

Why this matters for the Philippines and the world

Antimicrobial resistance does not respect borders. A patient in Manila, Mumbai or Madrid can face the same untreatable infection. The World Bank has warned that drug-resistant infections could cause global economic damage on par with the 2008 financial crisis.

For the Philippines, this patent is a point of pride. It shows that Filipino scientists can contribute to solving global problems, even with limited resources. The discovery could also spur more investment in local research and development, creating a pipeline of homegrown innovations.

What happens next depends on funding, regulatory approvals and successful trials. The University of San Agustin team is not resting. They are already working on refining the compound and expanding their screening programme to find more potential antibiotics.